Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value

Table 4 Association between the proliferation markers Ki67, MCM2 and Geminin and other prognostic factors in 309 cases of early breast cancer

Clinico-pathological Feature	Categories	Ki67 median	p-value	MCM2 median	p-value	Geminin Median	p- value
Age^a	</= 50 years	10	0.006	31.6	0.097	3.4	0.101
Age^a	>50 years	7	0.006	21.3	0.097	3	0.101
Grade^b	1	4.5	<0.001	16.5	<0.001	0.5	<0.001
	2	7		20.7		2.7
	3	14.7		50		6.3
ER status^a	Positive	6.7	<0.001	19.1	<0.001	2.3	<0.001
ER status^a	Negative	14.6	<0.001	50	<0.001	8.1	<0.001
LN status^a	Positive	7.5	0.787	24	0.734	3	0.387
LN status^a	Negative	8	0.787	24.67	0.734	3	0.387
HER2^ac status	Positive	9	0.299	30	0.298	3	0.039
HER2^ac status	Negative	12.7	0.299	37	0.298	8.3	0.039
Tumour size^b	</= 2 cm	7.5	0.034	23.4	0.197	2.6	0.132
	>2, < 5 cm	7.1		24.3		3
	>/= 5 cm	14.5		37.5		5.7

^aMann Whitney test used to test the association between 2 continuous, unpaired variables
^bKruskal-Wallis test used to test the association among 3 continuous, unpaired variables
^cOnly 155 cases with known HER2 status were included to test the association of HER2 status with each of the proliferation markers

ISSN: 1471-2407